IL2 and glomerulonephritis: Compared with WT-IL-2 and PBS treatment, L72-FSY and PEG-L72FSY treatment significantly ameliorated lupus disease severity, as determined by reduced levels of autoantibodies, including anti-nuclear antibodies (ANAs), anti-ribonucleoprotein (rRNP) antibodies and anti-Smith (anti-Sm) antibodies, as well as marked improvements in kidney damage, as evidenced by the amelioration of glomerulonephritis, renal inflammation, and tubular degeneration and decreases in immunoglobulin deposition and proteinuria (Fig. 6a and Supplementary Fig. 16b, c).